SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures, with traders weighing winter weather forecasts, storage reports and pipeline or LNG supply disruptions. Bulls see potential for weather-driven demand and supply tightness, while bears point to mild-weather expectations, ample production and the leveraged funds compounding and futures-roll risks.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is drawing attention as traders bet on weaker natural-gas prices, pointing to large storage injections, ample production, and expectations of mild weather or a warm winter. Others see potential support from heat-driven demand, LNG or pipeline disruptions, and tighter storage, leaving the discussion focused on volatile swings and the risks of holding a leveraged ETF.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline: FDA clearance to expand its recurrent glioblastoma trial and upcoming GBM data, alongside completion of enrollment in its pancreatic cancer study. Traders are broadly bullish on the approaching clinical milestones, while some point to price consolidation and note that early results still need validation in larger cohorts.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that the U.S. would not strike Iran have fueled hopes for a relief bounce, but traders remain divided over whether the conflict and elevated oil prices still threaten markets. Attention is also on a packed week of Fed decisions, major tech earnings, and GDP and inflation data, adding to expectations for volatility.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention as traders watch upcoming earnings and its role supplying indium-phosphide substrates for AI data-center optics. Bulls point to AI-driven demand and growth potential, while bears focus on the stocks sharp volatility, rich valuation, and China-related supply risks.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention around Brazils presidential runoff, with traders positioning for a possible Flvio Bolsonaro win that they view as more market-friendly. Optimistic call activity and the ETFs sharp run-up are countered by downside hedges and concerns that the result may already be priced in, keeping the focus on election-driven volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys run toward record highs and anticipation of its quarterly report are driving attention, with traders expecting continued Mounjaro and Zepbound demand to support results and guidance. The outlook is broadly bullish, though some traders question the stocks valuation and flag intensifying competition in oral obesity drugs.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Fears of renewed U.S.-Iran conflict and disruption to oil flows around the Strait of Hormuz and Saudi infrastructure are driving crude higher and lifting USO. Traders are split between expecting the supply-risk rally to continue and betting on a sharp reversal if tensions ease or a deal emerges; some also warn that high oil could fuel inflation and pressure equities.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer trial updates, including data on J&Js investigational JNJ-6143 and apalutamide, are driving attention. Traders are broadly optimistic about the oncology news, while debating whether it can sustain a share-price recovery or is already reflected in the stock.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio is drawing attention ahead of its upcoming earnings report, with traders watching whether growth and demand can sustain a recent rebound. The discussion is split between bullish pre-earnings momentum and caution that reported growth includes carrier pass-through fees, making organic growth and expansion excluding those fees important measures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) to Present at 2026 ThinkEquity Conference on Oct. 15

Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

Cartilage repair is intended to do more than simply reduce pain. Ideally, proper treatment should also restore the cartilage tissue responsible for the smooth movement and durability of a healthy joint. Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing a regenerative approach designed to address that challenge&#8230; Read More&#62;&#62; This content was disseminated on behalf [&#8230;]

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments [&#8230;]

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for… Read More>> This content has been disseminated on behalf of Regentis Biomaterials Ltd. […]

Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather […]

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Why Did RGNT Stock Surge More Than 850% Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>On May 1, the company proposed a public offering of 3.33 million ordinary shares at an assumed price of $3 per share.</li><li>Regentis had also granted underwriters a 45-day option to purchase up to 500,000 additional shares.</li><li>Regentis’ lead therapy GelrinC is being evaluated in a Phase III trial, with more than 50% patients already enrolled.</li></ul>Shares of Regentis Biomaterials (RGNT) ripped past 850% on Monday to a fresh all-time high, as investors cheered the withdrawal of a proposed public share offering.<a href="https://stocktwits.com/symbol/RGNT">RGNT shares</a> also clocked their biggest-ever single-day gains.<h2 class="st-heading-2">RGNT Withdraws Proposed Public Offering</h2>On Monday, Regentis Biomaterials filed an application with the Securities and Exchange Commission (SEC) to withdraw its Form F-1 registration statement, indicating that it no longer plans to proceed with a proposed public offering announced last month.On May 1, the company proposed a firm-commitment public offering of 3.33 million ordinary shares at an assumed price of $3 per share, which would have raised about $10 million before expenses. The company also granted the underwriters a 45-day option to purchase up to 500,000 additional shares to cover any over-allotments.<h2 class="st-heading-2">RGNT Preparing For European Comemrcialization Of GelrinC</h2>Regentis Biomaterials is a regenerative medicine company developing tissue-repair treatments, with an initial focus on orthopedic conditions. Its lead product, GelrinC, is a hydrogel implant designed to help regenerate damaged knee cartilage.Earlier this month, the company said GelrinC was being evaluated in a Phase III U.S. trial, with more than 50% patients already enrolled. Regentis said it is positioning itself for potential European commercialization, completion of the study, and eventual FDA submission.<h2 class="st-heading-2">What Does Retail Think Of RGNT?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, while message volumes saw a mammoth 22,600% increase in the same time frame.One user expects the stock to rally even further after hours.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/656483387</stembedurl>The stock has gained more than 98% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-gains-eyes-on-breakout/cZKfp1LR73n">HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Regentis Biomaterials filed a notice to withdraw its Form F-1 registration statement, indicating that it did not wish to proceed with a proposed public offering announced last month.

Regentis Biomaterials

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.28
Prev Close	$1.40
Open	$1.42
Dividend Yield	0.00%
50-Day Moving Average	$1.85
Beta	3.45
Avg. Volume	54,085.63
PE Ratio	-0.52

52-Week High	$15.50
52-Week Low	$1.23
Market Capitalization	$8.99M
EPS (Annual)	-$2.64
Price to Book	1.17
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

RGNT Fundamentals